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A report on the Precision Medicine: Personal Genomes
and Pharmacogenomics meeting, Cold Spring Harbor
Laboratory, USA, November 13–16, 2013.clinics do not have a molecular diagnosis. Christine EngBench to bedside
Precision medicine has come a long way in the past year.
Whole exome sequencing is now being used clinically,
with the exponential growth in the number of exomes
sequenced in recent years resulting in data repositories
that aim to facilitate clinical interpretation. This wealth
of information is prompting researchers and clinicians
to question their responses to secondary findings and to
ask who owns this valuable genetic information. Under-
standing these data will require developments in bio-
informatics and, crucially, databases, and the scale of
recent advances has led to an exploration of cloud com-
puting technologies. The rate of progress is now so fast
that Richard Durbin (Wellcome Trust Sanger Institute,
UK) made the prediction that it is conceivable we will
reach the point where every genomic variation possible
will have been observed.
Of all the applications of genomics to precision medi-
cine, genomic diagnostics stands out for its remarkable
progress, and this was the theme of the first session of the
meeting. Hugh Rienhoff (Children’s Hospital Oakland
Research Institute, USA) opened the meeting by describ-
ing his journey to find a genomic answer to his daughter’s
condition, and the eventual identification of a functional
mutation in the gene for transforming growth factor-beta.
A larger scale search for genomic answers was outlined by
Leslie Biesecker (National Human Genome Research
Institute, National Institutes of Health, USA), whose team
has developed an integrated genome-to-phenotype
approach to assess the clinical consequences of a set of
loss-of-function variants in a cohort of 870 exomes, a* Correspondence: kaitchis@ualberta.ca
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medium, for 12 months following its publicat
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phenotyping. A clinically significant phenotype was found
in approximately 2% to 3% of patients, which was higher
than expected.
About half of current attendees at medical genetic
(Baylor College of Medicine, USA) presented the Baylor
pipeline for whole exome sequencing in a clinically
accredited laboratory to identify causative mutations
underlying disease phenotypes; this approach was suc-
cessful in approximately 25% of undiagnosed patients.
The Baylor team filter their results with a regularly
updated, internally annotated gene list before clinical
reporting by a team of clinicians and genetic counselors;
they also implement three levels of review, ending up
with a ‘sign-out’ conference. They report the 56 medi-
cally actionable genes recommended by the American
College of Medical Genetics, but also include mutations
that are predicted to be deleterious in genes that do not
currently have an association with disease. Of note, 11
patients (of the 250 examined) had two molecular
diagnoses, challenging the traditional aim to find a
‘single unifying diagnosis’.
Tim Hubbard (Wellcome Trust Sanger Institute, UK)
outlined the 100 K Genome Project (Genomics England),
which aims to sequence up to 100,000 patients over the
next five years to identify pathogenic mutations for rare
diseases, common cancers with high mortality, and infec-
tious diseases. Companies able to provide annotation that
can run inside the National Health Service firewall as an
app will be sought in a competitive process. Patients will
receive their data if they consent to do so.
Ekta Khurana and Michael Cromer (Yale University,
USA) presented work from the functional group of the
1000 Genomes project, in which non-coding candidate
cancer driver mutations were identified in somatic
variants. A specific example was a somatic mutation that
alters the DNA-binding motif of transcription factor YY1
found in 14 patients with insulin-producing adenomas.
Subsequent exome sequencing identified that one-third
of insulinomas had this mutation, which was not found
in other types of pancreatic tumors.Med Central Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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gression of disease and especially to uncover the mecha-
nisms of acquired resistance. Maja Krajinovic (Centre
Hospitalier Universitaire Sainte-Justine Research Center,
Canada) described her study of the 20% of patients with
acute lymphoblastic leukemia who are resistant to treat-
ment with asparaginase (a standard component in the
treatment of childhood acute lymphoblastic leukemia).
She identified mutations in ATF5 and ASNS associated
with an adverse drug reaction to asparaginase derived
from Escherichia coli. Also in this session, Christopher
Miller (Washington University School of Medicine,
USA) described methods for detecting cryptic subclones
in cancer that might be resistant to treatment and result
in post-treatment metastasis.
Looking for the limit in locus heterogeneity
One of the most successful applications for exome
sequencing and related techniques to date has been the
detection of copy number variants. Mathew Hurles
(Wellcome Trust Sanger Institute, UK) provided an update
on the Deciphering Developmental Disorders initiative,
which has so far recruited 7,048 families out of the planned
12,000 families. By using exome arraycomparative genomic
hybridization, the consortium has shown that 12% of
children have de novo single nucleotide variants or indels.
Of note, 2.7% of children previously assessed with a clinical
grade comparative genomic hybridization microarray were
found to have pathogenic copy number variants, compared
with 6.1% of those with no previous clinical grade
microarray. Claudia Gonzaga-Jauregui (Baylor College of
Medicine, USA) demonstrated the power of exome sequen-
cing and custom array comparative genomic hybridization
in identifying genes causative for Charcot-Marie-Tooth
disease, for which the symptom complex includes
neuropathy. Over 40% of a group of 40 patients with a
neuropathy without a known genetic cause were provided
with a genetic diagnosis and, interestingly, many patients
had mutations in more than one neuropathy gene. Tomasz
Gambin (Baylor College of Medicine, USA) presented
2,211 exomes from the Baylor dataset and 232 exomes
from Johns Hopkins University, USA, with many unique
variants identified (more than 50% novel). There was
some difference in pathological classification using the
Human Gene Mutation Database in comparison with the
ClinVar database (National Center for Biotechnology
Information, USA), although the results were broadly
similar.
The session on genomic variation in common traits and
disease drew a lot of attention. One highlight was the
presentation by Lauren Weiss (University of California
Santa Cruz, USA), who reported a systematic evaluation
of autism traits in the RASopathies caused by activat-
ing mutations in the Ras/MAPK signaling pathway:neurofibromatosis type 1, Noonan syndrome, Costello syn-
drome and cardiofaciocutaneous syndrome. Probands with
the four major RASopathies were compared to individuals
with idiopathic autism spectrum disorders and siblings with
no disorders (controls); those with RASopathies were
shown to have more severe autism traits. Genome-wide
association study data provided evidence of gene-gene
interactions between the Ras/MAPK pathway and other
genomic loci (similar to those seen in cancer epistasis),
resulting in different phenotypes of autism. It was hypothe-
sized that pharmaceuticals developed to target the Ras/
MAPK pathway could be useful in developmental dis-
orders. Treatment of these disorders therefore stands to
benefit in the short-term from advances in genomic
technology applied to personalized medicine.Pharmacogenetics in the clinic
The adoption of pharmacogenetics into clinical practice
has historically been slow, but it was clear at this meet-
ing that implementation of pharmacogenomics is now
underway. Adam Gordon (University of Washington,
USA) presented a new high-throughput sequencing
platform, PGRNseq, targeting 84 genes (including 2 kb
upstream) with strong associations to drug phenotypes.
This platform is being deployed by the Electronic
Medical Records and Genomics network, in which
patients due to receive a relevant drug will be se-
quenced, actionable variants identified, and this informa-
tion deposited in the patient’s electronic medical record,
with decision support for clinicians. Initial data from the
first 900 samples revealed many novel and rare variants,
including newly described truncating variants in import-
ant pharmacogenes such as CYP2C19 and DPYD.
Mary Relling (St Jude Children’s Research Hospital,
USA) outlined the work of the Clinical Pharmacogenet-
ics Implementation Consortium in developing peer-
reviewed, publicly available gene-drug pair guidelines
that provide specific recommendations on how to use
genetic test results to guide prescribing. St Jude uses the
DMETPlus Array (an array designed to assay for over
1,900 variants in genes relevant to the absorption, distri-
bution, metabolism and excretion of prescribed medica-
tions), along with a CYP2D6 copy number assay. It has
taken 2.5 years to incorporate data from four genes
(CYP2D6, CYP2C19, TPMT, SLCO1B1) into the elec-
tronic medical records. On a related theme, Catherine
Brownstein (Boston Children’s Hospital, USA) described
the hospital’s Clinical Pharmacogenomics Service, and
demonstrated that they have made cost savings following
the analysis of a relatively small number of gene-drug
pairs. This has laid the foundation for the Clinical
Pharmacogenomics Service becoming a billable service,
and provides a potentially generalizable model.
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One topic raised in multiple sessions that will be
increasingly important in the future was the return of
incidental findings, and this was the focus of Holly
Tabor’s talk (University of Washington, USA). She pro-
vided an in-depth study of participant preferences
regarding the return of incidental or secondary findings;
95% of patients in her sample said they would prefer
unrestricted access to their incidental findings regardless
of how applicable it was to their own known clinical
condition. Interestingly, surveyed clinicians were more
cautious in their recommendations for return of data.
The meeting concluded with an overview of the evolu-
tion of the technologies currently available and a preview
of emerging technologies. It was evident both in the final
session and throughout this meeting that the pace of the
precision medicine field continues to quicken and,
although questions remain, the findings from research
are set to move from the bench to the bedside in the
foreseeable future.
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